Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: FASEB J. 2022 Oct;36(10):e22514. doi: 10.1096/fj.202200765R

Figure 5: Combinatorial Ara-C/venetoclax treatment regimen augments metabolism of CNL to long chain ceramide metabolites.

Figure 5:

A-E:. MOLM-14 cells were treated with CNL 15μM, Ara-C 1.25μM, venetoclax 50nM alone or in combinations as indicated for 24 hours, prior to lipid analyses. Shown are total ceramide levels (A), individual ceramide species (A-C), ratios of the change in long-chain C16- to very-long-chain C24:1-ceramide (D), and levels of sphingosine and sphingosine-1-phosphate (E). N= 4–5, shown are means +/− S.E.M. * p < 0.02 to Vehicle; # p<0.001 to CNL/Ara-C/venetoclax (A); ^, p<0.005 to vehicle (E).